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Abstract
Background
Evidence for pharmacogenetic risk stratification of angiotensin-converting enzyme inhibitor
(ACEI) treatment is limited. Therefore, in a cohort of ACEI-treated patients with congestive
heart failure (CHF), we investigated the predictive value of two pharmacogenetic scores
that previously were found to predict ACEI efficacy in patients with ischemic heart disease
and hypertension, respectively. Score A combined single nucleotide polymorphisms
(SNPs) of the angiotensin II receptor type 1 gene (rs275651 and rs5182) and the bradykinin
receptor B1 gene (rs12050217). Score B combined SNPs of the angiotensin-converting
enzyme gene (rs4343) and ABO blood group genes (rs495828 and rs8176746).
Methods
Danish patients with CHF enrolled in the previously reported Echocardiography and Heart
Outcome Study were included. Subjects were genotyped and categorized according to
pharmacogenetic scores A and B of1, 2 and3 each, and followed for up to 10 years. Dif-
ference in cumulative incidences of cardiovascular death and all-cause death were
assessed by the cumulative incidence estimator. Survival was modeled by Cox proportional
hazard analyses.
Results
We included 667 patients, of whom 80% were treated with ACEIs. Differences in cumulative
incidences of cardiovascular death (P = 0.346 and P = 0.486) and all-cause death (P =
0.515 and P = 0.486) were not significant for score A and B, respectively. There was no
difference in risk of cardiovascular death or all-cause death between subjects with score
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A1 vs. 2 (HR 1.03 [95% CI 0.79–1.34] and HR 1.11 [95% CI 0.88–1.42]), score A1 vs.
3 (HR 0.80 [95% CI 0.59–1.08] and HR 0.91 [95% CI 0.70–1.20]), score B1 vs. 2 (HR
1.02 [95% CI 0.78–1.32] and HR 0.98 [95% CI 0.77–1.24]), and score B1 vs.3 (HR 1.03
[95% CI 0.75–1.41] and HR 1.05 [95% CI 0.79–1.40]), respectively.
Conclusions
We found no association between either of the analyzed pharmacogenetic scores and fatal
outcomes in ACEI-treated patients with CHF.
Introduction
The prevalence of congestive heart failure (CHF) is increasing and CHF now affects approxi-
mately 10% of subjects above 60 years, with an overall 5-year mortality rate remaining at 50%
[1–3]. Angiotensin-converting enzyme inhibitors (ACEIs) reduce mortality and morbidity in
patients with CHF and therefore represent a cornerstone in the current pharmacologic man-
agement of this disease [4, 5]. The clinical response to treatment with ACEIs, however, displays
substantial inter-individual variability in terms of both safety and efficacy, and genetic variabil-
ity of patients contributes to this phenomenon [6–8]. Accordingly, selected genetic variants
have been proposed for pharmacogenetic risk stratification of patients treated with ACEIs in
attempt to individually tailor such treatment [9–11]. Notably, two distinct genetic scores based
on single nucleotide polymorphisms (SNPs) in the angiotensin II receptor type 1 gene
(AGTR1) and bradykinin receptor B1 gene (BDKRB1), as well as the ACE gene (ACE) and
ABO blood group genes (ABO), respectively, were recently found to predict ACEI efficacy and
ACE activity in European patients with stable ischemic heart disease (IHD) and in Asian
patients with young-onset hypertension, respectively [9–12]. Therefore, we examined the pre-
dictive value of these two genetic scores in a cohort of ACEI-treated patients with CHF.
Materials and Methods
Study population and endpoints
This retrospective cohort study was based on patients participating in the previously reported
Echocardiography and Heart Outcome study (ECHOS), a randomized, double-blinded, pla-
cebo-controlled trial of nolomirole (a mild inhibitor of the sympathetic nerve system) in
patients with severe CHF, where nolomirole was found to possess no beneficial or harmful
effects after 2.5 years of follow-up [13]. In the period 2001–2002, ECHOS included 1000
patients>18 years of age from centers in Denmark, Norway and Sweden admitted with New
York Heart Association (NYHA) class II-IV CHF and an echocardiographic left ventricular
wall motion score index1.2 (corresponding to an ejection fraction 35%) [13]. Among
exclusion criteria were uncorrected hemodynamically significant valvular disease and acute
myocardial infarction within one month. Approximately 80% of ECHOS patients were treated
with ACEIs and for the present study, criteria for inclusion were participation in ECHOS, Dan-
ish citizenship and availability of DNA for genotyping. Patients were followed from hospital
discharge until occurrence of a study endpoint or a maximum of 10 years. Our primary end-
point was cardiovascular (CV) death and the secondary endpoint was all-cause death. Since
nolomirole had no effects on clinical outcomes in the ECHOS trial and as the drug therefore
was discontinued hereafter, we did not differentiate between patients who received nolomirole
Pharmacogenetic Risk Stratification in ACEI Treatment
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and those who received placebo. Information on baseline treatment with ACEIs, beta-blockers,
aldosterone antagonists, diuretics, and insulin was available from the ECHOS dataset, which
also supplied information on NYHA class, wall motion score index, IHD, diabetes mellitus,
chronic obstructive pulmonary disease, atrial fibrillation, body mass index, and smoking status.
Information on vital status and individual average annual gross income (socioeconomic status)
throughout the 5-year period prior to inclusion was obtained from the National Causes of
Death Registry and the Danish Central Person Registry, respectively [14].
Genetic analyses
The first genetic score (score A) used for the current study was previously found to be associ-
ated with reduced ACEI treatment benefit in European patients with stable IHD, and was
based on three SNPs, i.e., rs275651 and rs5182 located in AGTR1 and rs12050217 in BDKRB1,
respectively [11]. The second genetic score (score B) was previously reported to be associated
with systemic ACE activity and response to ACEI treatment in patients of Asian descent
with young-onset hypertension [10]. This score also consisted of three SNPs, i.e., rs4343
located in ACE, which is in high linkage disequilibrium (LD) with the ACE I/D polymorphism
(rs1799752), and rs495828 and rs8176746 of ABO, respectively. In the original reports, both
genetic scores A and B assigned one score point to the respective responder allele of each geno-
type [10, 11]. Because alleles can occur in a homozygous or heterozygous form, each genotype
could contribute with a maximum of two score points. As an exception to this rule, however,
score B assigned only 1 point for rs495828 if the responder allele occurred in homozygote
form, and 1 point for rs8176746, irrespective of whether the responder allele appeared in het-
erozygous or homozygous form [10]. Thus, there were a maximum of 6 achievable points with
score A, but only 4 achievable points for score B. Moreover, due to the relatively undersized
sample in the current study, we condensed both genetic scores to include only three individual
score levels which was also done in the original study for score A, i.e., with1, 2, and3 score
points [11]. By this method, the number of patients within each score level was increased, as
was the statistical power of the study. Because recent fine-mapping of ACE revealed a break
point in an LD block that was significantly associated with ACE activity in an Asian popula-
tion, we examined an additional SNP in ACE (rs4353) in order to tag the gene on either side of
the recombinant break point [12]. The seven selected SNPs were genotyped by use of TaqMan
SNP genotyping reagents, specific primers and probes (Applied Biosystems, Foster City, CA,
USA). We used two different PCR master mixtures. For the genotyping of rs495828, rs5182,
and rs275651, the TaqMan Universal PCRMaster Mix was used (Applied Biosystems, Foster
City, CA, USA). Genotyping of SNPs rs4343, rs4353, rs8176746 and rs12050217 was done
using KAPA PROBE FAST qPCR Kit Master Mix (2x) ABI Prism (Kapa Biosystems, Inc., Wil-
mington, MA, USA). Amplification conditions were as recommended by the manufacturers of
the PCR master mixtures.
Statistics
Chi-square tests were used to examine if the genotype frequencies were distributed according
to the Hardy-Weinberg equilibrium. Information on six additional ACE SNP genotypes in
European and Asian (Han Chinese) populations, respectively, were obtained from the Interna-
tional HapMap Project [15]. Haploview was applied to determine and visualize LD relation-
ships between SNPs in this gene [16].
Incidence rates (IRs) for each of the two study endpoints expressed as events per 100 per-
son-years were calculated for patients with1, 2 or3 score points for score A and B, respec-
tively. The Chi-Square test and Student’s t-test were used to examine differences in categorical
Pharmacogenetic Risk Stratification in ACEI Treatment
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and continuous baseline characteristics. Cumulative incidences were assessed by Gray’s non-
parametric test as well as the Aalen-Johansen cumulative incidence estimator, both modeled
for compering risk with CV death [17]. Cox proportional hazard analyses were used to model
survival. In analyses of survival data, patients entered the model at the date of discharge from
the index hospitalization where they were randomized in the ECHOS study. The survival anal-
yses were performed at up to 10 years of follow-up (main analysis) and 5 years of follow-up
(sensitivity analysis), respectively. The analyses exclusively included ACEI-treated patients,
and patients without ACEI treatment were only included for selected additional analyses to
examine the predictive value of the genetic scores in non-ACEI-treated patients, as well as for
an over-all assessment of interactions between the genetic scores and ACEI treatment status.
Additionally, the predictive capacity of score A was evaluated separately in ACEI-treated
patients with ischemic and non-ischemic CHF, respectively, as the value of this score was origi-
nally demonstrated in patients with IHD [11]. Finally, subgroup analyses of CV death in
patients treated with the three most frequently used ACEIs in the study were done for both
scores. Survival analyses were adjusted for age, sex, IHD, NYHA class, wall motion score index,
diabetes mellitus, chronic obstructive pulmonary disease, and insulin treatment, which have all
previously been associated with mortality in the ECHOS population [18]. In addition, analyses
were adjusted for socioeconomic status. The proportional hazard assumption, linearity of con-
tinuous variables, and absence of interaction, respectively, were tested and found valid if not
otherwise stated. A two sided P value0.05 was considered statistical significant. Analyses and
data management were performed in SAS version 9.3 (SAS Institute Inc. Cary, North Carolina)
and R version 3.0.2 (R Foundation for Statistical Computing, Vienna, Austria).
Ethics
This project was approved by the Danish National Committee on Health Research Ethics (pro-
tocol no. H-15006089) and by the Danish Data Protection Agency (protocol no. 2007-58-
0015/GEH-2010-001). All files were anonymized prior to data management and statistical
analyses. ECHOS was approved by authorities in the participating countries as well as by rele-
vant ethics committees and was conducted in accordance with the Declaration of Helsinki III
and Guidelines for Good Clinical Practice in the European Union. All patients gave their writ-
ten informed consent prior to participation [13].
Results
Study population
Of the 1000 patients originally randomized in ECHOS, 667 patients of Danish citizenship had
DNA available for genotyping. Of these 525 (79%) patients were treated with ACEIs and 349
(52%) patients had IHD. The three most frequently used ACEIs were trandolapril (40% of
patients), ramipril (25%), and perindopril (16%), which were dispensed in mean daily doses of
2.4 (SD 1.2) mg, 6.2 (SD 3.1) mg, and 3.3 (SD 1.0) mg, respectively (Tables 1 and 2). There
were no significant differences in baseline characteristics between patients with different num-
ber (1, 2, or3) of score points for scores A and B, except for the distribution of patients
treated with trandolapril in score B (Tables 1 and 2). The distribution of patients with1, 2
or3 score points were 293 (43.9%), 215 (32.2%) and 159 (23.8%) for score A, and 276
(41.4%), 261 (39.1%) and 130 (19.5%) for score B. The mean follow-up time for the total study
population was 5.1 (SD 3.6) years. Mean (SD) follow-up times for patients with1, 2 or3
score points were 5.6 (3.6), 5.0 (3.6), and 5.9 (3.5) years for score A, and 5.5 (3.7), 5.5 (3.7), and
5.3 (3.2) years for score B, respectively.
Pharmacogenetic Risk Stratification in ACEI Treatment
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Population genetics
Allele and genotype frequencies calculated in the total study population and in patients with
and without ACEI treatment, respectively, are shown in Table 3. Furthermore, P values for the
deviation from Hardy-Weinberg equilibrium are shown for each SNP in Table 3. There was a
lower degree of LD in ACE among Han Chinese than in European HapMap individuals. This
was evident from lower R2 values for the pairwise associations of SNP alleles across the recom-
binant breakpoint between rs4344 and rs4353 previously identified in Chinese subjects (Fig 1)
Table 1. Baseline clinical characteristics for patients with genetic score A.
Score A 1 Score A = 2 Score A 3 Total P value
Number of patients 293 215 159 667
Male gender 206 (70.3) 161 (74.9) 120 (75.5) 487 0.3756
Age (mean [SD] years) 70.07 (12.21) 69.91 (11.33) 70.04 (10.72) 70.01 (11.57) 0.9612
Socioeconomic class
Low 169 (57.7) 140 (65.1) 98 (61.6) 407 0.2326
High 124 (42.3) 75 (34.9) 61 (38.4) 260 0.2326
Comorbidity
Diabetes 48 (16.4) 35 (16.4) 30 (18.9) 113 0.7704
Ischemic heart disease 159 (54.3) 112 (52.3) 78 (49.1) 349 0.5706
COPD 59 (20.1) 46 (21.5) 38 (24.1) 143 0.6276
Atrial ﬁbrillation 91 (31.1) 67 (31.8) 55 (34.6) 213 0.7372
Previous coronary procedure
CABG 43 (14.7) 33 (15.4) 25 (15.7) 101 0.9494
PCI 19 (6.5) 11 (5.1) 11 (6.9) 41 0.7343
Medication
ACEIs * 232 (79.7) 171 (79.9) 122 (78.2) 525 0.9101
- Trandolapril 91 (31.1) 74 (34.4) 47 (29.6) 212 0.6146
- Ramipril 65 (22.2) 37 (17.2) 28 (17.6) 130 0.3058
- Perindopril 38 (13.0) 28 (13.0) 20 (12.7) 86 0.9967
- Enalapril 18 (6.1) 19 (8.8) 16 (10.1) 53 0.2726
- Captopril 7 (2.4) 6 (2.8) 4 (2.5) 17 0.9617
- Lisinopril 4 (1.4) 4 (1.9) 4 (2.5) 12 0.6665
- Quinapril 1 (0.3) 1 (0.5) 1 (0.6) 3 0.9048
- Fosinopril 1 (0.4) 0 (0.0) 0 (0.0) 1 0.5290
Beta-blockers 146 (50.2) 111 (51.9) 80 (51.3) 337 0.928
Aldosterone antagonists 155 (53.3) 129 (60.3) 91 (58.3) 375 0.2611
Diuretics 287 (98.6) 208 (97.2) 153 (98.1) 648 0.5199
Insulin 27 (9.3) 13 (6.1) 7 (4.5) 47 0.1324
Nolomirole 136 (46.2) 111 (34.3) 77 (48.4) 324 0.5714
Clinical measures
NYHA 2.28 (0.64) 2.27 (0.64) 2.31 (0.59) 2.28 (0.63) 0.6826
WMI 0.84 (0.23) 0.84 (0.25) 0.85 (0.23) 0.84 (0.24) 0.5595
Body mass index 26.06 (4.75) 26.02 (5.11) 26.66 (5.36) 26.20 (5.02) 0.3112
Smoker 94 (32.8) 64 (30.0) 51 (32.5) 209 0.7963
COPD: chronic obstructive pulmonary disease; CABG: coronary artery bypass graft; PCI: percutaneous coronary intervention; ACEI: angiotensin-
converting enzyme inhibitor; NYHA: New York Heart Association; WMI: wall motion index.
* A total of 11 ACEI-treated patients lacked information on the speciﬁc type of ACEI.
doi:10.1371/journal.pone.0144195.t001
Pharmacogenetic Risk Stratification in ACEI Treatment
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[12]. The six examined ACE SNPs were highly correlated in the European HapMap population
as suggested by high R2 values for all pairwise comparisons without evidence of a recombinant
breakpoint. In the ECHOS population rs4343, a neighbour of rs4344, and rs4353 were also
highly correlated (Fig 1). Hence, rs4343 and rs4353 were redundant and the latter was excluded
in the subsequent statistical analyses.
Table 2. Baseline clinical characteristics for patients with genetic score B.
Score B 1 Score B = 2 Score B 3 Total P value
Number of patients 276 261 130 667
Male gender 190 (68.8) 197 (75.5) 100 (76.9) 487 0.1193
Age (mean [SD] years) 69.64 (11.50) 70.47 (11.55) 69.88 (11.84) 70.01 (11.57) 0.7014
Socioeconomic class
Low 161 (58.3) 161 (61.7) 85 (65.4) 407 0.3815
High 115 (41.7) 100 (38.3) 45 (34.6) 260 0.3815
Comorbidity
Diabetes 46 (16.7) 44 (16.9) 23 (17.7) 113 0.9706
Ischemic heart disease 155 (56.2) 129 (49.4) 65 (50.4) 349 0.2593
COPD 61 (22.1) 52 (20.0) 30 (23.3) 143 0.7257
Atrial ﬁbrillation 92 (33.6) 78 (30.1) 43 (33.1) 213 0.6709
Previous coronary procedure
CABG 46 (16.7) 35 (13.5) 20 (15.4) 101 0.5842
PCI 19 (6.9) 19 (7.3) 3 (2.3) 41 0.1248
Medication
ACEIs* 230 (84.2) 198 (76.4) 97 (75.2) 525 0.0350
- Trandolapril 103 (37.3) 84 (32.2) 25 (19.2) 212 0.0011
- Ramipril 56 (20.3) 48 (18.4) 26 (20.0) 130 0.8378
- Perindopril 31 (11.2) 35 (13.4) 20 (15.4) 86 0.4898
- Enalapril 20 (7.2) 20 (7.7) 13 (10.0) 53 0.6219
- Captopril 6 (2.1) 6 (2.3) 5 (3.8) 17 0.5783
- Lisinopril 4 (1.4) 3 (1.1) 5 (3.8) 12 0.1431
- Quinapril 1 (0.4) 1 (0.4) 1 (0.8) 3 0.8322
- Fosinopril 0 (0.0) 1 (0.4) 0 (0.0) 1 0.4957
Beta-blockers 133 (48.7) 137 (52.9) 67 (51.9) 337 0.6106
Aldosterone antagonists 157 (57.5) 145 (56.0) 73 (56.6) 375 0.9384
Diuretics 271 (99.3) 252 (97.3) 125 (96.9) 648 0.1538
Insulin 21 (7.7) 17 (6.6) 9 (7.0) 47 0.8778
Nolomirole 145 (52.4) 116 (44.3) 63 (48.5) 324 0.1727
Clinical measures
NYHA class 2.23 (0.63) 2.32 (0.65) 2.30 (0.58) 2.28 (0.63) 0.1778
WMI 0.84 (0.23) 0.86 (0.24) 0.83 (0.24) 0.84 (0.24) 0.9681
Body mass index 25.93 (4.69) 26.17 (5.25) 26.89 (5.26) 26.20 (5.02) 0.1265
Smoker 97 (35.7) 78 (30.5) 34 (26.4) 209 0.1465
COPD: chronic obstructive pulmonary disease; CABG: coronary artery bypass graft; PCI: percutaneous coronary intervention; ACEI: angiotensin-
converting enzyme inhibitor; NYHA: New York Heart Association; WMI: wall motion index.
* A total of 11 ACEI-treated patients lacked information on the speciﬁc type of ACEI.
doi:10.1371/journal.pone.0144195.t002
Pharmacogenetic Risk Stratification in ACEI Treatment
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Prognostic capacity of genetic score A
Crude IRs per 100 patient-years for both study endpoints are shown in Fig 2. The overall differ-
ence in cumulative incidence of CV death and all-cause death between patients with scores A
1, 2, and3, was not significant (P = 0.346 and P = 0.486, respectively). Cumulative inci-
dence plots for both endpoints are shown in Fig 3. There was no difference in risk of CV death
between patients with score A1 and 2, respectively (HR 1.03 [95% confidence interval (CI)
0.79–1.34], P = 0.817). However, compared with patients with score A1, a non-significant
nominal reduction in risk of CV death was found in patients with score A3 (HR 0.80 [95%
CI 0.59–1.08], P = 0.141) (Fig 2). HRs for all-cause death were 1.11 (95% CI 0.88–1.42,
Table 3. Allele and genotype frequencies for the total study population and patients treated with and without angiotensin-converting enzyme
inhibitors (ACEIs).
Gene SNP Group MAF Genotype frequencies HWE P value
Score A
AGTR1
rs275651 T AA TT AT
Total 0.18 0.67 0.03 0.30 0.6494
ACEI 0.18 0.67 0.03 0.29 0.8116
Non-ACEI 0.18 0.66 0.01 0.33 0.1460
rs5182 C CC TT CT
Total 0.49 0.22 0.25 0.53 0.0911
ACEI 0.47 0.21 0.27 0.52 0.2264
Non-ACEI 0.53 0.25 0.19 0.56 0.1403
BDKRB1
rs12050217 G AA GG AG
Total 0.22 0.62 0.05 0.33 0.6541
ACEI 0.22 0.62 0.06 0.33 0.3612
Non-ACEI 0.20 0.63 0.03 0.34 0.3786
Score B
ACE
rs4343 G GG AA GA
Total 0.49 0.24 0.26 0.49 0.7060
ACEI 0.48 0.24 0.27 0.48 0.4723
Non-ACEI 0.51 0.25 0.22 0.52 0.5517
rs4353 A AA GG AG
Total 0.49 0.24 0.26 0.51 0.7505
ABO
rs495828 T GG TT GT
Total 0.23 0.61 0.07 0.32 0.0383
ACEI 0.24 0.59 0.07 0.34 0.0488
Non-ACEI 0.17 0.69 0.04 0.28 0.7152
rs8176746 A CC AA CA
Total 0.07 0.87 0.01 0.12 0.9490
ACEI 0.06 0.88 0.01 0.11 0.9699
Non-ACEI 0.08 0.84 0.01 0.15 0.9939
MAF: Minor allele frequency. HWE: Hardy-Weinberg equilibrium. ACE: ACE gene; ABO: ABO blood type gene; AGTR1: angiotensin II receptor type 1
gene; BDKRB1: bradykinin receptor B1 gene.
doi:10.1371/journal.pone.0144195.t003
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P = 0.384) and 0.91 (95% CI 0.70–1.20, P = 0.509), for subjects with score A = 2 and3,
respectively, compared to patients with score A1 (Fig 2). Comparable results were found
when endpoints were calculated for ACEI-treated patients after 5 years of follow-up and in
Fig 1. Linkage disequilibrium (LD) relationships between single nucleotide polymorphisms (SNPs) in the genes encoding the angiotensin-
converting enzyme (ACE). The top of the figure shows the SNPs. A: HapMap Han Chinese population [15]; B: HapMap European population [15]; C:
Echocardiography and Heart Outcome study (ECHOS) population. The strength of LD was determined by R2 statistics. The decrease in LD in the Han
Chinese population probably reflects the previously reported recombinant breakpoint between rs4344 and rs4353 [12]. No such decrease in LD is observed
for the HapMap European population and was also not observed in the ECHOS population. The ACE I/D polymorphism was not included in the figure as it
has not been genotyped in the HapMap populations [15]. However, this polymorphism is located between rs4331 and rs4343, and is in high LD with these
two SNPs [12].
doi:10.1371/journal.pone.0144195.g001
Fig 2. Risk of cardiovascular (CV) death and all-cause death in angiotensin-converting enzyme
inhibitor-treated patients with congestive heart failure stratified by genetic score A. Results from
adjusted multivariate Cox proportional hazard analyses with score A1 used as reference. IR: Incidence rate
per 100 patient-years; HR: Hazard ratio. CI: confidence interval. Error bars illustrate 95% CIs.
doi:10.1371/journal.pone.0144195.g002
Pharmacogenetic Risk Stratification in ACEI Treatment
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additional analyses of patients not treated with ACEIs (Tables 4 and 5). Accordingly, no inter-
action was found between score A and ACEI treatment on CV death or all-cause death,
Fig 3. Cumulative incidence plots for cardiovascular (CV) death and all-cause death in angiotensin-converting enzyme inhibitor-treated patients
with congestive heart failure according to genetic score A and B. The plots show the cumulative incidence estimates in % plotted against follow-up time
in years. 95% confidence intervals are highlighted in gray scale nuances.
doi:10.1371/journal.pone.0144195.g003
Table 4. Risk of cardiovascular (CV) death and all-cause death with genetic scores A and B in patients
treated with angiotensin-converting enzyme inhibitors after 5 years of follow-up.
HR HR (CI) HR (CI) P value
Score A 1 Score A = 2 Score A 3
CV death 1.00 0.95 (0.73–1.24) 0.88 (0.65–1.19) 0.700
All-cause death 1.00 1.02 (0.80–1.30) 0.99 (0.76–1.30) 0.981
Score B 1 Score B = 2 Score B 3
CV death 1.00 1.03 (0.80–1.33) 1.09 (0.79–1.49) 0.876
All-cause death 1.00 0.97 (0.77–1.23) 1.08 (0.82–1.44) 0.757
HR: hazard ratio; CI: conﬁdence interval.
doi:10.1371/journal.pone.0144195.t004
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respectively, when both ACEI-treated and ACEI-nontreated patients were included in the
model (P = 0.789 and P = 0.858, respectively). In a subsequent analysis we tested the prognostic
capacity of score A in ACEI-treated patients with ischemic and non-ischemic CHF, respec-
tively, and found no change in risk of CV death amongst patients with ischemic CHF, with
HRs of 1.05 (95% CI 0.74–1.49, P = 0.797) and 0.98 (95% CI 0.66–1.44, P = 0.917), for patients
with score A = 2 and3 compared to score A1, respectively. However, there was a reduced
risk of CV death with increasing score A in patients with non-ischemic CHF, with HRs of 0.89
(95% CI 0.57–1.37, P = 0.585) and 0.56 (95% CI 0.33–0.96, P = 0.034) for those with score
A = 2 and3 compared to score A1. Accordingly, although there were overlapping CIs for
hazard rate ratios, the difference in risk of CV death between ACEI-treated patients with ische-
mic versus non-ischemic CHF, showed a trend for increased risk of CV death with increasing
score A in patients with ischemic CHF (P = 0.332 [Fig 4]). Finally, the prognostic value of score
A did not change when analyses were restricted to only include patients treated with trandola-
pril, ramipril or perindopril (Table 6).
Prognostic capacity of genetic score B
Crude IRs per 100 patients-years for both study endpoints are shown in Fig 5. The overall dif-
ference in cumulative incidence of CV death and all-cause death between patients with scores
Table 5. Risk of cardiovascular (CV) death and all-cause death with genetic scores A and B in patients
without angiotensin-converting enzyme inhibitor treatment after 10 years of follow-up.
HR HR (CI) HR (CI) P value
Score A 1 Score A = 2 Score A 3
CV death 1.00 1.12 (0.68–1.84) 0.87 (0.50–1.53) 0.707
All-cause death 1.00 1.30 (0.82–2.05) 0.98 (0.58–1.65) 0.450
Score B 1 Score B = 2 Score B 3
CV death 1.00 0.89 (0.52–1.48) 0.70 (0.37–1.28) 0.495
All-cause death 1.00 0.88 (0.54–1.42) 0.74 (0.42–1.31) 0.590
HR: hazard ratio; CI: conﬁdence interval.
doi:10.1371/journal.pone.0144195.t005
Fig 4. Difference in risk of cardiovascular death with different levels of genetic score A in angiotensin-converting enzyme inhibitor-treated
patients with congestive heart failure (CHF) and ischemic heart disease (IHD) compared with no IHD. Results from adjusted multivariate Cox
proportional hazard analyses. IR: Incidence rate per 100 patient-years; HRR: hazard rate ratio. Error bars illustrate 95% confidence intervals.
doi:10.1371/journal.pone.0144195.g004
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B1, 2, and3, was not significant (P = 0.515 and P = 0.486, respectively). Cumulative inci-
dence plots for both endpoints are shown in Fig 3. We found no difference in risk of CV death
or all-cause death between subjects with score B1, 2 or3, respectively (Fig 5), and there
was also no association between score B and either study endpoint after 5 years of follow-up
(Table 4). In addition, score B had no significant influence on the prognosis in patients not
treated with ACEIs (Table 5) and there was no interaction between score B and ACEI treat-
ment on CV death or all-cause death when both ACEI-treated and ACEI-nontreated patients
were included in the model (P = 0.799 and P = 0.699, respectively). Finally, the prognostic
value of score B did not change when analyses were restricted to only include patients treated
with trandolapril, ramipril or perindopril (Table 6).
Table 6. Risk of cardiovascular (CV) death with genetic scores A and B in patients treated with trandolapril, ramipril or perindopril.
HR HR (CI) HR (CI) P value
Score A 1 Score A = 2 Score A 3
Trandolapril 1.00 0.90 (0.61–1.35) 0.64 (0.39–1.05) 0.210
Ramipril 1.00 0.84 (0.42–1.66) 0.87 (0.43–1.74) 0.853
Perindopril 1.00 1.01 (0.48–2.14) 0.91 (0.40–2.07) 0.966
Score B 1 Score B = 2 Score B 3
Trandolapril 1.00 0.97 (0.65–1.47) 1.30 (70.73–2.30) 0.595
Ramipril 1.00 0.66 (0.32–1.39) 0.90 (0.41–1.97) 0.542
Perindopril 1.00 0.88 (0.40–1.90) 1.11 (0.47–2.61) 0.859
HR: hazard ratio; CI: conﬁdence interval.
doi:10.1371/journal.pone.0144195.t006
Fig 5. Risk of cardiovasclar (CV) death and all-cause death in angiotensin-converting enzyme inhibitor-treated patients with congestive heart
failure stratified by genetic score B. Results from adjusted multivariate Cox proportional hazard analyses with score B1 used as reference. IR: Incidence
rate per 100 patient-years; HR: Hazard ratio. CI: confidence interval. Error bars illustrate 95% CIs.
doi:10.1371/journal.pone.0144195.g005
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Discussion
In the present cohort study of ACEI-treated patients with CHF, we examined the prognostic
value of two distinct pharmacogenetic scores A and B that have previously been found to influ-
ence ACEI efficacy and ACE activity in patients with stable IHD and hypertension, respec-
tively. No association was found between these two scores and CV death and all-cause death
during up to 10 years of follow-up. These findings were corroborated by sensitivity analyses,
where endpoints were calculated after 5 years of follow-up and in analyses of patients not
treated with ACEIs. However, subgroup analyses showed a trend for increased mortality with
increasing score A in ACEI-treated patients with ischemic CHF compared with non-ischemic
CHF. Our study results therefore suggest that score A and B do not predict mortality in ACEI-
treated patients with CHF irrespective of etiology, but that score A may be of such value in
patients with ischemic CHF.
The individual response to various drugs used for treatment of CHF is highly variable and
this variability cannot solely be explained by differences in clinical characteristics of patients
[19–21]. Accordingly, genetic variations have been suggested to have a considerable effect on
drug response and in patients treated with ACEIs the ACE I/D polymorphism has been a focus
of attention [9, 22, 23]. Indeed, high circulating ACE activity has been associated with this
polymorphism and with worse cardiovascular outcomes in CHF patients [24]. Nonetheless, the
utility of the ACE I/D polymorphism for pharmacogenetic risk stratification in CHF patients
remains contentious, which may be explained, in part, by an anticipated small impact of this
polymorphism on ACEI efficacy, and by the fact that published results have been limited by
small study populations [22, 25, 26]. A few other genetic polymorphisms have separately been
associated with the efficacy and safety of ACEIs, including some of those represented in the
current study (rs4343, rs495828 and rs817646) [10, 27]. However, to our knowledge only one
study, which examined the SNPs comprising score A of our study in patients with stable IHD,
has hitherto used more than one SNP to provide an incremental pharmacogenetic risk score
for prediction of survival in ACEI-treated patients [9, 11, 22].
In the present study of patients with CHF treated with or without ACEIs, we did not find
any significant association between score A or B, and CV death and all-cause death, respec-
tively. It is likely that the effect sizes of the examined SNPs in score A and B were too small to
be detected in survival analyses. Also, the relatively small patient sample size of the study
reduced its statistical power. Previously, the prognostic importance of score A was documented
by a candidate gene (total of 12 genes) approach in patients with stable coronary artery disease
that were approximately 10 years younger than our patient population and had a 5-year mor-
tality<10%, while score B was derived from a genome-wide association study of patients of
around 40 years of age with hypertension that examined effects on plasma ACE activity [10,
11]. Indeed, in agreement with the complex biological networks regulating the renin-angioten-
sin-aldosterone system (RAAS) activity and ACEI pharmacokinetics and pharmacodynamics
in different cardiovascular disease states, ultimately only a polygenetic or genome-wide
approach in large populations of CHF patients treated with ACEIs may provide more definitive
answers. Of note, the genotype frequency of rs495828 of ABO in our study population was not
in Hardy-Weinberg equilibrium, but this aberration was only of borderline significance. There
was a higher degree of LD in ACE among the European HapMap individuals, where all investi-
gated SNPs were highly correlated as compared to the HapMap Project population of Han Chi-
nese subjects (Fig 1) [15]. Accordingly, we also found high correlation between the two tag
SNPs rs4343 and rs4353 in the ECHOS population. Previous fine-mapping of ACE amongst
Asian hypertensive patients identified a recombinant break point between rs4344 and rs4353
located adjacent to rs4343 that defined haplotypes with different ACE activities [12]. These
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different LD patterns of the examined SNPs between Europeans and Asians should be taken
into account in the interpretation of the results of the current study and those reported in the
literature [6–11].
Several large studies have shown that patients with ischemic CHF, independent of blood
pressure reduction, benefit from ACEI treatment with a relative reduction in fatal outcomes of
approximately 20% [19–21]. However, patients with ischemic CHF appear to have less
improvement in symptoms, inferior hemodynamic response, and more limited amelioration of
left ventricular dysfunction with contemporary anti-congestive treatment (including ACEIs) as
compared to patients with non-ischemic CHF, and IHD has been shown to independently pre-
dict mortality in patients with CHF [28–30]. Moreover, ischemic CHF has been associated
with more pronounced neuro-humoral activation and T-cell-mediated immune responses
[31]. These differences between ischemic and non-ischemic CHF might reflect important vari-
ations in relative contributions of systemic and local effects of RAAS as well as differences in a
range of other pathogenic and regulatory mechanisms [32, 33]. Accordingly, it is plausible that
patients with ischemic CHF respond differently to ACEIs as compared to patients with non-
ischemic CHF and these mechanisms may have contributed to our finding of increased risk of
CV death with increasing score A in patients with ischemic CHF only. Also, ACEIs differ in
their pharmacokinetic and pharmacodynamic profiles, e.g., with different lipophilicities and
tissue penetration, which is likely to influence their efficacy, albeit that we found comparable
results between the three most used ACEIs in our study, i.e., trandolapril, ramipril and peri-
ndopril, which differ in their lipophilicities [34–37]. Moreover, the relationship between sys-
temic RAAS inhibition vs. RAAS inhibition at the tissue and intracellular level in respective
pathophysiological target zones, e.g., arterial wall, heart, and kidney, respectively, is less clear at
present [33, 38]. Interestingly, reports have documented the existence of cross-talk between the
adrenergic system and RAAS, and treatment with beta-blockers and ACEIs may act through
shared pharmacodynamics pathways [39–41]. In this regard, a recently published pharmacoge-
netic study that was also conducted in the ECHOS population, showed increased risk of death
amongst carvedilol-treated patients with the combination of gain-of-function SNPs in the
adrenergic β-1 receptor gene (Arg-389-homozygous) and angiotensinogen gene (Thr174-ho-
mozygous), and a loss-of-function SNP in the adrenergic β-2 receptor gene (Gln27-carrier),
respectively [42]. These findings clearly highlight the necessity to include genetic variants from
several relevant pathophysiologic pathways in pharmacogenetic investigations of complex dis-
eases such as CHF.
Limitations
In addition to the considerations mentioned above, other limitations apply to the interpreta-
tion of the present work. For example, although the current study was based on a cohort of
patients with comparable baseline characteristics who were recruited for a randomized con-
trolled trial, the risk of unmeasured confounding is inherent to retrospective cohort studies.
Also, as opposed to score A, score B was originally associated with systemic ACE activity and
blood pressure response to ACEIs, but not directly with clinical outcomes in patients receiving
ACEIs [10, 11]. In addition, our study was limited by a relative small sample size and we did
not differentiate between different ACEIs (which can have different pharmacokinetic and
pharmacodynamic characteristics) or ACEI doses [34–36]. We did not measure plasma angio-
tensin II levels before and after ACEI treatment and were therefore not able to assess the level
of systemic ACE inhibition that was achieved. It should also be mentioned that the statistical
analyses were based on baseline characteristics of the study population and we did not correct
for possible changes in ACEI treatment over time, however, the proportion of patients with
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CHF initiated with ACEIs who still redeem their ACEI prescriptions after five years has in a
previous Danish registry study been found to be 79% [43].
Conclusion
The current study of patients with CHF treated with ACEIs did not find any significant associa-
tion between CV death and all-cause death and two genetic scores (score A and B) that have
previously been associated with ACEI efficacy. However, the analyses suggested a trend for
increased risk of CV death with increased score A in ACEI-treated patients with ischemic CHF
relative to non-ischemic CHF. While this finding warrants further study, genome-wide associa-
tion studies and analyses that incorporate multiple gene interactions may be necessary to pro-
vide more detailed insights into the potential role of pharmacogenetic risk stratification of
patients with CHF.
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